Related Experiment Videos
Quetiapine and breast feeding
Jonathan Rampono1, Judith H Kristensen, Kenneth F Ilett
1Department of Psychological Medicine, King Edward Memorial Hospital for Women, Subiaco, Western Australia.
The Annals of Pharmacotherapy
|March 22, 2007
Summary
Infant exposure to quetiapine via breast milk is minimal, less than 0.1% of the maternal dose, with no adverse effects observed in the infant. This suggests quetiapine is likely safe for breastfeeding mothers after risk assessment.
Area of Science:
- Pharmacology and Toxicology
- Neonatal and Maternal Health
Background:
- Quetiapine is an atypical antipsychotic used for various psychiatric conditions.
- Assessing medication safety during breastfeeding is crucial for infant well-being.
Observation:
- A case study involving a breastfeeding mother and her 3-month-old infant was conducted.
- Quetiapine levels in breast milk and infant plasma were measured using high-performance liquid chromatography.
Findings:
- The relative infant dose of quetiapine was found to be 0.09% of the maternal weight-adjusted dose.
- The milk:plasma ratio was 0.29, and infant plasma concentrations were 6% of maternal levels.
- No adverse effects were observed in the infant during the study period.
Implications:
- The low infant exposure suggests quetiapine may be a viable option for breastfeeding mothers.
- Careful individual risk-benefit analysis and infant monitoring are recommended.
- Further research is needed to confirm these findings in larger populations.
Related Concept Videos
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...